Stay updated with breaking news from 87162t20. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($6.06) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link. Madrigal Pharmaceuticals […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) will be releasing its earnings data before the market opens on Tuesday, May 7th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($6.06) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link. Madrigal Pharmaceuticals (NASDAQ:MDGL – Get […]
Analysts at Bank of America started coverage on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The firm set an “underperform” rating and a $150.00 price target on the biopharmaceutical company’s stock. Bank of America‘s target price would suggest a […]
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) fell 3.3% during mid-day trading on Wednesday . The company traded as low as $225.22 and last traded at $225.22. 43,731 shares were traded during trading, a decline of 92% from the average session volume of 525,723 shares. The stock had previously closed at $232.98. […]
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has received an average rating of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price […]